Seeking Alpha

Jeff Ramson's  Instablog

Jeff Ramson
Send Message
Founder and CEO of ProActive Capital Resources Group (PACRG), LLC, - over 25 years trading and investing. I employ technical analysis combined with discretionary analysis of global events and trends. I am equally comfortable from either long or short side of the markets. Owner of... More
My company:
ProActive NewsRoom
My blog:
The ProActive News Room
View Jeff Ramson's Instablogs on:
  • $ONVO Organovo: Organ Printing Innovator Featured In Wall Street Journal

    ProActive Capital Resources Group has received compensation from Organovo, to provide research and investor relations coverage for a period of time.

    Organovo (NYSEMKT:ONVO) is an emerging life science company that is developing innovative three-dimensional (3D) biology capabilities to create tissue on demand for research (e.g. drug discovery and toxicology) and surgical applications (e.g. therapeutic regenerative medicine implants) based on its proprietary NovoGen MMX Bioprinter technology (YouTube video:

    The tremendous game-changing potential for this technology was recently featured in a Wall Street Journal article (available at

    The Company is advancing beyond the current 2D mono-layer cell standard in the life science industry by creating 3D human tissue constructs comprised entirely of cells to better replicate human biology inside the body (in vivo) with the advantage of lab-based (in vitro) applications that do not depend on human or animal subjects for testing purposes.

    $ONVO has broad intellectual property (NYSE:IP) rights including exclusive licenses from the University of Missouri-Columbia and Clemson University in addition to full ownership of six pending patent applications related to 3D bio-printing technology.

    The Company's three-part business model includes the following:

    1.) Preclinical drug discovery activities (development milestone and royalty-based business model) such as research agreements with pharmaceutical and biotech companies including current agreements with Pfizer (NYSE:PFE) to develop 3D tissue models for drug development purposes and United Therapeutics (NASDAQ:UTHR) to discover new treatments for a lung condition (pulmonary hypertension).

    2.) Life science research tools (product sales-based business model) such as pharmacokinetic (ADME or absorption, distribution, metabolism and excretion)testing for experimental drug compounds and toxicology (TOX) testing (e.g. liver TOX testing is very common since this is the primary route of metabolism for most drugs) to predict how drugs will in humans without subjecting people or animals to testing with experimental compounds.

    3.) A next-generation strategy for regenerative medicine that offers the potential for 3D tissue constructs comprised entirely of functional cells without the need for non-cellular scaffold or bio-material components for surgical implantation to restore normal organ or tissue function in humans following acute or chronic damage or injury with the potential to erase the need for organ transplants / rejection since this technology utilizes a patient's own cells.

    $ONVO anticipates new agreements with biotech and/or pharmaceutical companies within the next 18-24 months and has increased its resources on both business development and R&D (research and development) to improve the conversion rate (i.e. from negotiations to signed deals) and the terms of drug discovery pacts such as the current agreements with $PFE and $UTHR (i.e. from low to mid/high single-digit royalties and $10M to $20M+ development milestone payments), which are expected to generate revenue during 2H12.

    The Company's goal is to both talk with more companies regarding potential agreements (business development) while simultaneously generating data (R&D) that is published in peer-reviewed scientific journals to validate the 3D bio-printing technology (e.g. liver TOX data). $ONVO also plans to enter strategic technology partnerships with bio-engineering focused companies that may specialize in complementary areas such as cell growth mediums.

    While the process of preclinical drug discovery and development is a lengthy, risky one; $ONVO represents a truly innovative life science company with the potential to change how drugs are discovered, developed and tested in addition to tremendous opportunity in the area of tissue/organ repair and/or replacement-possibly erasing the need for organ transplants and the concern of rejection with an initial goal of "printing" new blood vessels that could be used after a heart attack to restore blood flow and minimize damage.

    Sep 21 9:51 AM | Link | 3 Comments
  • $FPMI FluoroPharma: Developing Better Cardio Imaging Agentsto Improve Patient Outcomes

    ProActive Capital Resources Group has received compensation from FluoroPharma to provide research and investor relations coverage for a period of time.

    FluoroPharma Medical, Inc. (OTCQB: FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (NYSEARCA:CAD). Below is a summary of the Company's pipeline:

    1.) BFPET is being evaluated in an on going investigator-sponsored Phase 1 clinical trial in China for imaging agent to measure cardiovascular blood flow with expected conclusion of the 20-patient study during 4Q12 to support start of planned Phase 2 trials. In late July, $FPMI announced high quality images were obtained in the study conducted by Dr. Alan Fischman, who is the former head of nuclear medicine at Massachusetts General Hospital.

    Dr. Fischman had a positive commentary on the results and potential of BFPET, stating, "Initial results are impressive. Image quality obtained using PET is superb. BFPET shows clear diagnostic qualities as well as increased resolution, inherent in PET. The initial images look spectacular and we are confident that when all the patients are imaged, the data will further support clinical development of the agent."

    2.) CardioPET is currently being evaluated in an open-label Phase 2 study as a diagnostic imaging agent to assess perfusion of the heart and fatty acid uptake in heart muscle in patients that have coronary artery disease. The study is being conducted at two sites in Belgium with results expected later this year.

    3.) VasoPET is being developed as a diagnostic imaging agent that accumulates in areas of inflammation, making it useful for the identification of patients that have experienced a heart attack or stroke that are at risk for a potential recurrence with a Phase 1 clinical trial expected to begin early next year.

    4.) AZPET is a development-stage imaging agent that attaches to brain a myloid plaques making them visible on a PET scan to allow for the early detection of Alzheimer's disease.

    With cardiovascular disease representing the leading cause of death worldwide, $FPMI is well positioned as an emerging diagnostic company in the space with several promising imaging agents with the potential to improve patient outcomes through more precise and targeted imaging results. In addition, the Company has an earlier stage asset for the early detection of Alzheimer's disease, which is in dire need of better diagnostic tests and treatments to slow or halt progression through early intervention and more effective treatments.

    Aug 30 3:27 PM | Link | Comment!
  • TGTX TG Therapeutics Expands Upon A Promising Anti-Cancer Pipeline

    ProActive Capital Resources Group has received compensation from TG Therapeutics, to provide research and investor relations coverage for a period of time.

    TG Therapeutics (NASDAQ:TGTX) is focused on the acquisition, development and commercialization of innovative treatments for cancer and other unmet medical needs with a summary of the Company's pipeline outlined below.

    1.) Ublituximab is a CD20-targeted anti-cancer monoclonal antibody that will be evaluated in a Phase I / II clinical trial expected to begin this quarter with final results expected late next year in up to 36 patients in the Phase I dose-escalation portion of the trial followed by up to 77 patients in the Phase 2 portion in patients with B-cell lymphomas that are relapsed or refractory to standard treatments such as RITUXAN.

    RITUXAN is the leading anti-CD20 product currently on the market with global sales in 2011 of about $7 billion and Ublituximab has been bio-engineered to specifically enhance the effects of RITUXAN for potentially additive anti-cancer effects for B-cell related disorders such as Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). In addition, anti-CD20treatments have demonstrated effectiveness for auto-immune conditions such as Rheumatoid Arthritis (NYSE:RA) and lupus in addition to the neurological disorder multiple sclerosis.

    Ublituximab has been evaluated in a two-part Phase 1clinical trial in France and was well tolerated with no major safety concerns along with encouraging signs of effectiveness and clinical benefit in patients with advanced forms of CLL. Ublituximab is manufactured by the Company's partner, LFB Biotechnologies, with ongoing plans to develop a new manufacturing method utilizing transgenic animal vectors through subsidiary GTC Bio therapeutics.

    2.) AST-726 is a nasally delivered formulation of hydroxocobalamin for the treatment of vitamin B12 deficiency. $TGTX has global rights toAST-726, which has demonstrated equivalence to the widely used intramuscular(NYSE:IM) injected formulation that is typically given once-monthly for B12deficiency. The Company expects to announce its development plans for AST-726within the next 6-12 months.

    3.) Earlier today, $TGTX announced an exclusive global (ex-India)development and commercialization agreement with Rhizen Pharmaceuticals forTGR-1202 (previously RP5264), which is classified as a highly specific, orally available PI3K (phosphoinositide-3-kinase) delta inhibitor for the treatment of blood-based cancers and autoimmune disorders based on preclinical results. The Company expects to file an Investigational New Drug (NYSE:IND) application with FDA during 4Q12 seeking clearance to begin clinical trials. Rhizen is eligible to receive over $250 million in potential development and sales-based milestone payments plus royalties on nets sales of the drug.

    Aug 16 10:36 AM | Link | Comment!
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.